Atossa Therapeutics (NASDAQ:ATOS - Free Report) had its price target boosted by Ascendiant Capital Markets from $6.50 to $7.00 in a report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.
Other equities research analysts have also recently issued reports about the company. StockNews.com cut Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, November 18th. HC Wainwright raised their target price on Atossa Therapeutics from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th.
View Our Latest Stock Report on Atossa Therapeutics
Atossa Therapeutics Stock Performance
Shares of ATOS traded up $0.03 during mid-day trading on Monday, hitting $1.25. The company's stock had a trading volume of 533,048 shares, compared to its average volume of 1,058,432. Atossa Therapeutics has a one year low of $0.70 and a one year high of $2.31. The firm has a market capitalization of $157.25 million, a PE ratio of -5.55 and a beta of 1.22. The stock's 50-day moving average is $1.38 and its two-hundred day moving average is $1.34.
Institutional Investors Weigh In On Atossa Therapeutics
A number of institutional investors have recently bought and sold shares of ATOS. Barclays PLC boosted its stake in shares of Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company's stock valued at $255,000 after purchasing an additional 123,683 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Atossa Therapeutics by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company's stock valued at $4,278,000 after purchasing an additional 44,762 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company's stock valued at $75,000 after purchasing an additional 24,951 shares in the last quarter. State Street Corp boosted its stake in shares of Atossa Therapeutics by 4.2% in the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company's stock valued at $2,633,000 after purchasing an additional 69,180 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics in the 3rd quarter valued at $75,000. Institutional investors and hedge funds own 12.74% of the company's stock.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Articles
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
